Stock ADXS AYALA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ayala Pharmaceuticals, Inc. Stock

Equities

ADXS

US0076244062

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 15:24:00 2024-05-02 EDT 		5-day change 1st Jan Change
0.5305 USD -17.51% Intraday chart for Ayala Pharmaceuticals, Inc. -1.76% -20.46%
04-16 Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
04-16 Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2022 692K 945K Sales 2023 13K 17.76K Capitalization 7.94M 10.84M
Net income 2022 -38M -51.91M Net income 2023 -48M -65.58M EV / Sales 2022 * -
Net cash position 2022 657K 898K Net Debt 2023 3.43M 4.69M EV / Sales 2023 875 x
P/E ratio 2022 *
-
P/E ratio 2023
-0.08 x
Employees 21
Yield 2022 *
-
Yield 2023
-
Free-Float 99.91%
More Fundamentals * Assessed data

Chart Ayala Pharmaceuticals, Inc.

Dynamic Chart

Latest news about Ayala Pharmaceuticals, Inc.

Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge DJ
North American Morning Briefing : Focus Turns to -2- DJ
Ayala Pharmaceuticals, Inc. Announces Departure of Roy Golan as Chief Financial Officer, Effective from June 25, 2024 CI
Andres Guttierez, Chief Medical Officer and Executive Vice President, Departs from Ayala Pharmaceuticals, Inc CI
North American Morning Briefing : Stocks Set for -2- DJ
Immunome, Inc. completed the acquisition of Assets from Ayala Pharmaceuticals, Inc.. CI
North American Morning Briefing : Fed's Preferred -2- DJ
North American Morning Briefing : Nvidia Ignites -2- DJ
Ayala Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 3 Ringside Study Evaluating AL102 in Desmoid Tumors CI
Sector Update: Health Care Stocks Gain Late Afternoon MT
Top Midday Gainers MT
Immunome to Acquire Potential Desmoid Tumor Treatment From Ayala Pharmaceuticals; Shares Climb MT
Immunome, Inc. entered into a definitive asset purchase agreement to acquire Assets from Ayala Pharmaceuticals, Inc. for $94.2 million. CI
More news

Analyst Recommendations on Ayala Pharmaceuticals, Inc.

North American Morning Briefing : Stocks Futures Steady on Rates Optimism DJ
North American Morning Briefing : Apple's China Conflict, Rate Hike Fears Continue to Weigh DJ
ADVAXIS : Alliance Global Adjusts Advaxis' Price Target to $2.25 From $5, Maintains Buy Rating MT
Advaxis Announces Updated Data at ASCO from a Phase 2 Study of AXAL in Advanced Cervical Cancer Showing Promising Survival Rates Consistent with Earlier Reports CI
More recommendations

Press releases Ayala Pharmaceuticals, Inc.

Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome AQ
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors AQ
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals AQ
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors AQ
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023 AQ
More press releases

Quotes and Performance

1 day-17.51%
1 week-1.76%
Current month-17.11%
1 month-17.11%
3 months-0.28%
6 months-37.59%
Current year-20.46%
More quotes

Highs and lows

1 week
0.52
Extreme 0.519
0.67
1 month
0.50
Extreme 0.5
0.70
Current year
0.50
Extreme 0.5
1.49
1 year
0.50
Extreme 0.5
1.49
3 years
0.50
Extreme 0.5
1.49
5 years
0.50
Extreme 0.5
1.49
10 years
0.50
Extreme 0.5
1.49
More quotes

Managers and Directors - Ayala Pharmaceuticals, Inc.

Managers TitleAgeSince
Ken Berlin CEO
 Chief Executive Officer 59 18-03-31
Roy Golan DFI
 Director of Finance/CFO 50 23-10-18
Shmuel Tuvia CTO
 Chief Tech/Sci/R&D Officer - 22-04-30
Members of the board TitleAgeSince
David Sidransky CHM
 Chairman 64 17-10-31
Roni Appel BRD
 Director/Board Member 57 04-10-31
Murray Goldberg BRD
 Director/Board Member 79 17-11-30
More insiders

Quotes

Date Price Change Volume
24-05-02 0.5305 -17.51% 5,485
24-05-01 0.6431 -3.29% 287
24-04-29 0.665 +19.82% 1,780
24-04-26 0.555 +0.91% 559
24-04-25 0.55 +1.85% 426

Delayed Quote OTC Markets, May 02, 2024 at 03:24 pm

More quotes

Company Profile

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). Aspacytarabine (BST-236) is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine. It is also focused on the development and commercialization of proprietary Listeria monocytogenes (Lm)-based antigen delivery products. These efforts are primarily focused on the development of ADXS-504, a Lm-based therapy for early-stage prostate cancer.
Sector
Biotechnology & Medical Research
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.5305
Average target price
-
Consensus

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
AYALA PHARMACEUTICALS, INC. Stock Ayala Pharmaceuticals, Inc.
-20.46% 27.42M
MODERNA, INC. Stock Moderna, Inc.
+26.28% 42.68B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.99% 42.4B
LONZA GROUP AG Stock Lonza Group AG
+45.32% 40.04B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.36% 24.94B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.47% 18.96B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.58% 12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.75% 11.95B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-2.02% 11.55B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ADXS Stock